Division of Oncology, Department of Paediatrics, All India Institute of Medical Science, New Delhi, India.
Dr BR Ambedkar Institute of Rotary Club and Hospital, All India Institute of Medical Science, New Delhi, India.
Pediatr Blood Cancer. 2018 Jun;65(6):e27001. doi: 10.1002/pbc.27001. Epub 2018 Feb 15.
Cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) genes are implicated in many malignancies including acute lymphoblastic leukemia (ALL). These tumor suppressor genes, with a key regulatory role in cell cycle are located on chromosome 9p21.3. Previous studies involving CDKN2A/B gene deletions have shown mixed associations with survival outcome in childhood ALL.
Hundred and four newly diagnosed children with ALL (1-14 years) were enrolled in this study. Genomic DNA from pretreatment bone marrow/peripheral blood samples of these children was investigated for copy number alterations in CDKN2A/B genes using multiplex ligation dependent probe amplification assay. Immunophenotype subtyping and cytogenetic and molecular analysis of ALL was performed at start of induction chemotherapy in all children. Children were monitored for response to prednisolone (Day 8), complete morphological remission, and minimal residual disease at the end of induction. The minimum postinduction follow-up period was 6 months.
CDKN2A/B deletions were seen in 19.8% (18/91) of B lineage acute lymphoblastic leukemia (B-ALL) and 38.5% (5/13) of T lineage acute lymphoblastic leukemia (T-ALL). Monoallelic CDKN2A/B deletions were found in 61.1% of total deletions in B-ALL while all the children with T-ALL harbored biallelic deletions. The prevalence of CDKN2A/B gene deletions was found to be significantly higher in older children (P = 0.002), in those with higher leukocyte count (P = 0.037), and in National Cancer Institute high risk group patients (P = 0.001) in the B-ALL subgroup. Hazard ratio was significantly high for children with CDKN2A/B deletions in total cohort (P = 0.004). Children with CDKN2A/B deletion had significantly lesser event free survival (P = 0.03).
CDKN2A/B deletions were significantly more prevalent in T-ALL subgroup and were found to have higher hazard ratio and lesser event free survival in total cohort in our study.
细胞周期蛋白依赖性激酶抑制剂 2A/B(CDKN2A/B)基因与包括急性淋巴细胞白血病(ALL)在内的多种恶性肿瘤有关。这些肿瘤抑制基因在细胞周期中具有关键的调节作用,位于染色体 9p21.3 上。先前涉及 CDKN2A/B 基因缺失的研究表明,其与儿童 ALL 的生存结果存在混合关联。
本研究纳入了 104 例新诊断的 ALL 患儿(1-14 岁)。使用多重连接依赖性探针扩增检测这些患儿预处理骨髓/外周血样本中 CDKN2A/B 基因的拷贝数改变。所有患儿在诱导化疗开始时进行免疫表型亚分型、细胞遗传学和分子分析。在诱导治疗第 8 天监测患儿对泼尼松的反应、完全形态学缓解和诱导结束时的微小残留病。最小的诱导后随访时间为 6 个月。
91 例 B 系急性淋巴细胞白血病(B-ALL)中有 19.8%(18/91)和 13 例 T 系急性淋巴细胞白血病(T-ALL)中有 38.5%(5/13)存在 CDKN2A/B 缺失。在 B-ALL 中,总缺失的 61.1%为单等位基因 CDKN2A/B 缺失,而所有 T-ALL 患儿均存在双等位基因缺失。B-ALL 亚组中,CDKN2A/B 基因缺失在年龄较大的患儿(P=0.002)、白细胞计数较高的患儿(P=0.037)和国家癌症研究所高危组患儿(P=0.001)中更为常见。在总队列中,CDKN2A/B 缺失患儿的风险比显著升高(P=0.004)。CDKN2A/B 缺失的患儿无事件生存率显著降低(P=0.03)。
在本研究中,T-ALL 亚组中 CDKN2A/B 缺失更为常见,且在总队列中风险比更高,无事件生存率更低。